JPH04321624A - Antiphlogistic analgestic plaster - Google Patents
Antiphlogistic analgestic plasterInfo
- Publication number
- JPH04321624A JPH04321624A JP11673291A JP11673291A JPH04321624A JP H04321624 A JPH04321624 A JP H04321624A JP 11673291 A JP11673291 A JP 11673291A JP 11673291 A JP11673291 A JP 11673291A JP H04321624 A JPH04321624 A JP H04321624A
- Authority
- JP
- Japan
- Prior art keywords
- parts
- styrene
- crotamiton
- isoprene
- block copolymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000202 analgesic effect Effects 0.000 title claims abstract description 14
- 239000002260 anti-inflammatory agent Substances 0.000 title claims abstract description 7
- 230000001741 anti-phlogistic effect Effects 0.000 title abstract 5
- 239000011505 plaster Substances 0.000 title abstract 4
- DNTGGZPQPQTDQF-XBXARRHUSA-N crotamiton Chemical compound C/C=C/C(=O)N(CC)C1=CC=CC=C1C DNTGGZPQPQTDQF-XBXARRHUSA-N 0.000 claims abstract description 34
- 229960003338 crotamiton Drugs 0.000 claims abstract description 33
- 229920000346 polystyrene-polyisoprene block-polystyrene Polymers 0.000 claims abstract description 31
- QRZAKQDHEVVFRX-UHFFFAOYSA-N biphenyl-4-ylacetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1C1=CC=CC=C1 QRZAKQDHEVVFRX-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000004615 ingredient Substances 0.000 claims abstract description 12
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 17
- 230000001760 anti-analgesic effect Effects 0.000 claims description 5
- NPPJLSILDPVHCM-UHFFFAOYSA-N Felbinac ethyl Chemical compound C1=CC(CC(=O)OCC)=CC=C1C1=CC=CC=C1 NPPJLSILDPVHCM-UHFFFAOYSA-N 0.000 claims description 4
- 239000000730 antalgic agent Substances 0.000 claims description 3
- 229940079593 drug Drugs 0.000 abstract description 17
- 239000003814 drug Substances 0.000 abstract description 17
- 230000002085 persistent effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 29
- 238000009472 formulation Methods 0.000 description 26
- 229940057995 liquid paraffin Drugs 0.000 description 23
- 238000004519 manufacturing process Methods 0.000 description 23
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 22
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 21
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 21
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 21
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 20
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 20
- 150000002148 esters Chemical class 0.000 description 20
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 20
- 239000000126 substance Substances 0.000 description 18
- 229920002367 Polyisobutene Polymers 0.000 description 17
- -1 liquid paraffin Substances 0.000 description 8
- 239000002674 ointment Substances 0.000 description 6
- 229920005989 resin Polymers 0.000 description 6
- 239000011347 resin Substances 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000155 melt Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
- 239000000123 paper Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 2
- 235000019482 Palm oil Nutrition 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 241000020719 Satsuma Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 239000002385 cottonseed oil Substances 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 229960001193 diclofenac sodium Drugs 0.000 description 2
- ZOWQTJXNFTWSCS-IAQYHMDHSA-N eptazocine Chemical compound C1N(C)CC[C@@]2(C)C3=CC(O)=CC=C3C[C@@H]1C2 ZOWQTJXNFTWSCS-IAQYHMDHSA-N 0.000 description 2
- 229950010920 eptazocine Drugs 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 229960000192 felbinac Drugs 0.000 description 2
- 229960002428 fentanyl Drugs 0.000 description 2
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 2
- 229960002390 flurbiprofen Drugs 0.000 description 2
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 2
- 229960000991 ketoprofen Drugs 0.000 description 2
- 229960004752 ketorolac Drugs 0.000 description 2
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- OXROWJKCGCOJDO-JLHYYAGUSA-N lornoxicam Chemical compound O=C1C=2SC(Cl)=CC=2S(=O)(=O)N(C)\C1=C(\O)NC1=CC=CC=N1 OXROWJKCGCOJDO-JLHYYAGUSA-N 0.000 description 2
- 229960002202 lornoxicam Drugs 0.000 description 2
- 229960002373 loxoprofen Drugs 0.000 description 2
- YMBXTVYHTMGZDW-UHFFFAOYSA-N loxoprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1CC1C(=O)CCC1 YMBXTVYHTMGZDW-UHFFFAOYSA-N 0.000 description 2
- 229960001929 meloxicam Drugs 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 239000004745 nonwoven fabric Substances 0.000 description 2
- 239000002540 palm oil Substances 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 229960002702 piroxicam Drugs 0.000 description 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 2
- 229920002857 polybutadiene Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229920006132 styrene block copolymer Polymers 0.000 description 2
- 229920003002 synthetic resin Polymers 0.000 description 2
- 239000000057 synthetic resin Substances 0.000 description 2
- 150000003505 terpenes Chemical class 0.000 description 2
- 235000007586 terpenes Nutrition 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- 235000014692 zinc oxide Nutrition 0.000 description 2
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- ROGIWVXWXZRRMZ-UHFFFAOYSA-N 2-methylbuta-1,3-diene;styrene Chemical compound CC(=C)C=C.C=CC1=CC=CC=C1 ROGIWVXWXZRRMZ-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 229920000298 Cellophane Polymers 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- 239000013032 Hydrocarbon resin Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 239000005062 Polybutadiene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000277331 Salmonidae Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 1
- 229960001113 butorphanol Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229920006270 hydrocarbon resin Polymers 0.000 description 1
- 239000011256 inorganic filler Substances 0.000 description 1
- 229910003475 inorganic filler Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 229960005301 pentazocine Drugs 0.000 description 1
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 229920001568 phenolic resin Polymers 0.000 description 1
- 239000005011 phenolic resin Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920001083 polybutene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000010734 process oil Substances 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 229920003051 synthetic elastomer Polymers 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
【０００１】0001
【産業上の利用分野】本発明はスチレン−イソプレン−
スチレンブロック共重合体、クロタミトン及び消炎鎮痛
薬を必須成分とする消炎鎮痛貼付剤に関するものである
。[Industrial Application Field] The present invention relates to styrene-isoprene-
This invention relates to an anti-inflammatory analgesic patch containing a styrene block copolymer, crotamiton, and an anti-inflammatory analgesic as essential ingredients.
【０００２】0002
【従来の技術】消炎鎮痛薬を含有する貼付剤において、
基剤として天然ゴム、ポリアクリル酸系のポリマー、合
成ポリイソプレンゴム、ポリスチレン・ポリブタジエン
ゴム、ポリイソブチレン、シリコーンゴム、スチレン−
イソプレン−スチレンブロック共重合体等の親油性ポリ
マー、テルペン樹脂、石油樹脂、エステルガム等の粘着
付与剤、プロセスオイル、ポリブテン、流動パラフィン
、ヒマシ油、綿実油、パーム油、ヤシ油、ラノリン等の
軟化剤、亜鉛華、二酸化チタン、シリカ系の充填剤の各
基剤を適宜配合処方した例は当業者において広く知られ
ているところである。また消炎鎮痛薬の中でも４−ビフ
ェニル酢酸及び４−ビフェニル酢酸エチルエステルはゲ
ル軟膏剤（特開昭５９−２２２４０９ 号公報）あるい
は脂肪乳剤（特開昭６１−４４８０９号公報）の注射剤
としてすでに市販されている。[Prior Art] In a patch containing an anti-inflammatory analgesic,
Natural rubber, polyacrylic acid-based polymer, synthetic polyisoprene rubber, polystyrene/polybutadiene rubber, polyisobutylene, silicone rubber, styrene as a base material.
Softening of lipophilic polymers such as isoprene-styrene block copolymers, tackifiers such as terpene resins, petroleum resins, ester gums, process oils, polybutene, liquid paraffin, castor oil, cottonseed oil, palm oil, coconut oil, lanolin, etc. Those skilled in the art are well aware of examples in which the base materials of filler, zinc white, titanium dioxide, and silica filler are appropriately mixed and formulated. Among anti-inflammatory analgesics, 4-biphenylacetic acid and 4-biphenylacetic acid ethyl ester are already commercially available as gel ointments (Japanese Unexamined Patent Publication No. 59-222409) or fat emulsions (Japanese Unexamined Patent Publication No. 61-44809) as injections. has been done.
【０００３】0003
【発明が解決しようとする課題】上記に記載した公知又
は周知の貼付剤処方で消炎鎮痛貼付剤としても薬効成分
の消炎鎮痛薬が基剤や溶剤等に対する溶解性が悪く、結
晶析出の発生、経皮吸収性、薬効発現性、薬効持続性等
において充分ではなく生物学的利用率の点で問題がある
。又、消炎鎮痛薬の中でも難溶性の４−ビフェニル酢酸
又はそのエチルエステル化合物についての貼付製剤はほ
とんど検討されておらず、しかも、ゲル軟膏剤又は注射
剤のみで定量的投与方法としては問題があった。[Problems to be Solved by the Invention] When used as an anti-inflammatory and analgesic patch with the above-mentioned known or well-known patch formulation, the anti-inflammatory and analgesic agent as a medicinal ingredient has poor solubility in bases, solvents, etc., and crystal precipitation occurs. It is not sufficient in percutaneous absorption, medicinal efficacy development, medicinal efficacy persistence, etc., and there is a problem in bioavailability. Furthermore, among anti-inflammatory analgesics, there have been few studies on patch preparations for poorly soluble 4-biphenylacetic acid or its ethyl ester compound, and furthermore, there are problems with quantitative administration methods using only gel ointments or injections. Ta.
【０００４】0004
【課題を解決するための手段】本発明は、前述した問題
点を解決すべく鋭意研究した結果、スチレン−イソプレ
ン−スチレンブロック共重合体、クロタミトン及び消炎
鎮痛薬を必須成分とする配合処方とすることにより、解
決しうることを見い出し本発明を完成させたものである
。特に消炎鎮痛薬の中でも４−ビフェニル酢酸（一般名
：フェルビナク）はアルコール類、水、グリコール類、
イソプロピルミリステート等の各種溶媒に不溶又は難溶
であるため、各基剤と配合しても消炎鎮痛薬である４−
ビフェニル酢酸が充分に溶解せず結晶の形で基剤中に取
り込まれ、皮膚に対する吸収及び薬効発現性が思わしく
なかった。そこで鋭意研究した結果、意外にもクロタミ
トンが極めて溶解能力に優れていることを見い出した。
又、クロタミトンと各種親油性ポリマーとの配合につい
ても種々検討したところ、スチレン−イソプレン−スチ
レンブロック共重合体との配合が最も好ましいことを見
い出した。又４−ビフェニル酢酸エチルエステル（一般
名：フェルビナクエチル）を配合しても同様に好ましい
結果を得ることを見い出した。[Means for Solving the Problems] As a result of intensive research to solve the above-mentioned problems, the present invention provides a combination formulation containing styrene-isoprene-styrene block copolymer, crotamiton, and an anti-inflammatory analgesic as essential ingredients. By doing so, we have found a solution and completed the present invention. Among anti-inflammatory analgesics, 4-biphenylacetic acid (generic name: Felbinac) is especially effective against alcohol, water, glycols, etc.
Because it is insoluble or poorly soluble in various solvents such as isopropyl myristate, it is an anti-inflammatory analgesic even when combined with various bases.
Biphenylacetic acid was not sufficiently dissolved and was incorporated into the base in the form of crystals, resulting in poor skin absorption and medicinal efficacy. As a result of intensive research, it was surprisingly discovered that crotamiton has extremely excellent dissolving ability. Further, after various studies were conducted on the blending of crotamiton and various lipophilic polymers, it was found that blending with a styrene-isoprene-styrene block copolymer is most preferable. It has also been found that similarly favorable results can be obtained by blending 4-biphenylacetic acid ethyl ester (common name: felvinaquethyl).
【０００５】更に本発明の各基剤の配合処方をより詳細
に検討したところ、スチレン−イソプレン−スチレンブ
ロック共重合体５〜５０重量％、更に好ましくは１０〜
３０重量％、クロタミトン１〜２０重量％、更に好まし
くは２〜１０重量％、消炎鎮痛薬 ０．１〜１０重量％
、更に好ましくは ０．５〜５重量％からなる配合処方
とすることにより最も本発明の効果を現すことを見い出
した。[0005] Further, a more detailed study of the formulation of each base material of the present invention revealed that the styrene-isoprene-styrene block copolymer content is 5 to 50% by weight, more preferably 10 to 50% by weight.
30% by weight, crotamiton 1-20% by weight, more preferably 2-10% by weight, anti-inflammatory analgesic 0.1-10% by weight
It has been found that the effects of the present invention can be best exhibited by a formulation containing, more preferably, 0.5 to 5% by weight.
【０００６】尚、消炎鎮痛薬としては、すでに市販され
ている薬剤あるいは治験薬として臨床されている薬剤を
意味し、例えばインドメタシン、ケトプロフェン、フル
ルビプロフェン、ロキソプロフェンナトリウム、ジクロ
フェナックナトリウム、ピロキシカム、メロキシカム、
ベルモプロフェン、ロルノキシカム、ケトロラック、モ
ルヒネ、ブプレノルフィン、ブトルファノール、ペンタ
ゾシン、フェンタニール、エプタゾシン等が挙げられる
。[0006] Anti-inflammatory and analgesic drugs refer to drugs that are already on the market or are being clinically used as investigational drugs, such as indomethacin, ketoprofen, flurbiprofen, loxoprofen sodium, diclofenac sodium, piroxicam, meloxicam,
Examples include belmoprofen, lornoxicam, ketorolac, morphine, buprenorphine, butorphanol, pentazocine, fentanyl, eptazocine, and the like.
【０００７】本発明の貼付剤には、上記必須成分に加え
従来公知の酸化防止剤、例えばジブチルヒドロキシトル
エン等、軟化剤、例えば流動パラフィン、ヒマシ油、綿
実油、パーム油、ヤシ油、ラノリン等、粘着付与剤、例
えばロジン系樹脂〔エステルガム（荒川化学）、ハリエ
スター（薩摩化成）、ハリタック（薩摩化成）〕、テル
ペン系樹脂〔ＹＳレジン（安原油脂）、ピコライト（ハ
ーキュリーズ）〕、石油系樹脂〔アルコン（荒川化学）
、レガレッシ（ハーキュリーズ）、エスコレック（エク
ソン）、ウイングタック（グッドイヤー）〕、フェノー
ル系樹脂、キシレン系樹脂等、無機充填剤、例えば酸化
亜鉛、酸化アルミニウム、二酸化チタン、シリカ類、酸
化マグネシウム、酸化鉄、ステアリン酸亜鉛等の配合が
適宜適量含有される。In addition to the above-mentioned essential ingredients, the patch of the present invention contains conventionally known antioxidants such as dibutylhydroxytoluene, softeners such as liquid paraffin, castor oil, cottonseed oil, palm oil, coconut oil, lanolin, etc. Tackifiers, such as rosin resins [Ester Gum (Arakawa Chemical), Hariestar (Satsuma Kasei), Haritac (Satsuma Kasei)], terpene resins [YS Resin (cheap crude oil), Picolite (Hercules)], petroleum resins [Alcon (Arakawa Chemical)
, Legaressi (Hercules), Escolec (Exxon), Wingtac (Goodyear)], phenolic resins, xylene resins, etc., inorganic fillers such as zinc oxide, aluminum oxide, titanium dioxide, silicas, magnesium oxide, iron oxide, A suitable amount of zinc stearate and the like may be included.
【０００８】又、本発明の支持体としては、薬物の放出
に影響しないものが望ましく、伸縮性及び非伸縮性のも
のが用いられる。例えば合成樹脂膜としてポリエチレン
、ポリプロピレン、ポリブタジェン、エチレン酢酸ビニ
ル共重合体、ポリ塩化ビニル、ポリエステル、ナイロン
、ポリウレタン等のフィルム又はシートあるいはこれら
の積層体、多孔質体、発泡体、紙、布及び不織布等より
選択される。[0008] The support used in the present invention is preferably one that does not affect the release of the drug, and both stretchable and non-stretchable supports are used. For example, as a synthetic resin membrane, films or sheets of polyethylene, polypropylene, polybutadiene, ethylene vinyl acetate copolymer, polyvinyl chloride, polyester, nylon, polyurethane, etc., or laminates, porous bodies, foams, paper, cloth, and nonwoven fabrics thereof are used. Selected from etc.
【０００９】次に、本発明の消炎鎮痛貼付剤の製造法に
ついて説明する。まず、スチレン−イソプレン−スチレ
ンブロック共重合体、軟化剤、粘着付与剤及び充填剤等
を適宜所定の割合で加え混合物となし、窒素気流中で加
熱攪拌して溶解物とする。攪拌時の温度は １１０〜２
００ ℃であり、攪拌時間は３０〜１２０ 分間である
。Next, a method for producing the anti-inflammatory and analgesic patch of the present invention will be explained. First, a styrene-isoprene-styrene block copolymer, a softener, a tackifier, a filler, and the like are added in appropriate predetermined proportions to form a mixture, and the mixture is heated and stirred in a nitrogen stream to form a melt. The temperature during stirring is 110~2
00° C., and the stirring time is 30 to 120 minutes.
【００１０】次に、薬効成分及びクロタミトンの混合物
を前記溶解物の攪拌時の温度 １１０〜２００ ℃の範
囲内で添加し５〜３０分間混合して均一な溶解物を得る
。次に、この溶解物をドクターロール、リバースロール
等の展延機を用いて支持体に展延塗布する。支持体には
合成樹脂膜、紙、布、不織布等から選択して用いる。溶
解物を支持体に展延塗布した後、その上に剥離被覆物を
貼合するが、剥離処理をほどこした剥離紙、セロファン
又はポリエチレン、ポリプロピレン、ポリエステル等の
フィルムから適宜選択できる。以上述べた製造法により
本発明の貼付剤が得られる。[0010] Next, a mixture of medicinal ingredients and crotamiton is added to the above-mentioned melt at a stirring temperature of 110 to 200°C, and mixed for 5 to 30 minutes to obtain a uniform melt. Next, this melt is spread and coated on a support using a spreading machine such as a doctor roll or a reverse roll. The support is selected from synthetic resin membranes, paper, cloth, non-woven fabrics, and the like. After the melt is spread and coated on a support, a release coating is laminated thereon, and can be appropriately selected from release-treated release paper, cellophane, or a film made of polyethylene, polypropylene, polyester, or the like. The patch of the present invention can be obtained by the manufacturing method described above.
【００１１】[0011]
【実施例】以下、実施例、試験例を挙げて本発明をより
詳細に説明する。なお、実施例、比較例、参考例中、部
とあるのはすべて重量部を意味する。[Examples] The present invention will be explained in more detail below with reference to Examples and Test Examples. In addition, in Examples, Comparative Examples, and Reference Examples, all parts mean parts by weight.
【００１２】実施例１
スチレン−イソプレン−スチレンブロック共重合体
５０．０ 部 （商品名
カリフレックス ＴＲ−１１０７） 流動パラフィン
４６．９ 部
ブチルヒドロキシトルエン
２．０
部 クロタミトン
１．０ 部 ４−ビフェニル酢酸
０．１ 部 この処方で上
記の製造法に従い作成し、所望の大きさに切断し貼付剤
とした。Example 1 Styrene-isoprene-styrene block copolymer 50.0 parts (trade name
Califlex TR-1107) Liquid paraffin
46.9 parts
butylated hydroxytoluene
2.0
Part Crotamiton
1.0 part 4-biphenylacetic acid
0.1 part This formulation was prepared according to the above manufacturing method and cut into desired sizes to prepare a patch.
【００１３】実施例２
スチレン−イソプレン−スチレンブロック共重合体
５．０ 部 （商品名
カリフレックス ＴＲ−１１０７） 流動パラフィ
ン
３５．０ 部
ブチルヒドロキシトルエン
２．０
部 粘着付与剤（脂環族飽和炭化水素樹脂）
２８．０ 部
（商品名 アルコン Ｐ−１００） クロタミ
トン
２０．０
部 ４−ビフェニル酢酸
１０．０ 部 この処方で上記の製造法に従い
作成し、所望の大きさに切断し貼付剤とした。Example 2 Styrene-isoprene-styrene block copolymer 5.0 parts (trade name
Califlex TR-1107) Liquid paraffin
35.0 parts butylated hydroxytoluene
2.0
Part Tackifier (alicyclic saturated hydrocarbon resin)
28.0 parts (Product name Alcon P-100) Crotamiton
20.0
Part 4-biphenylacetic acid
10.0 parts This formulation was prepared according to the above manufacturing method and cut into desired sizes to prepare a patch.
【００１４】実施例３
スチレン−イソプレン−スチレンブロック共重合体
２６．０ 部 （商品名
カリフレックス ＴＲ−１１０７） 流動パラフィ
ン
４２．０ 部
ブチルヒドロキシトルエン
２．０
部 粘着付与剤（ロジンエステル）
１５．
０ 部 （商品名 ＫＥ−３１１）
クロタミトン
１０．０ 部 ４−ビフェニル酢酸
５．０ 部 この処方で上記の
製造法に従い作成し、所望の大きさに切断し貼付剤とし
た。Example 3 Styrene-isoprene-styrene block copolymer 26.0 parts (trade name
Califlex TR-1107) Liquid paraffin
42.0 parts butylated hydroxytoluene
2.0
Part Tackifier (rosin ester)
15.
0 parts (Product name KE-311) Crotamiton
10.0 parts 4-biphenylacetic acid
5.0 parts This formulation was prepared according to the above manufacturing method and cut into desired sizes to prepare a patch.
【００１５】実施例４
スチレン−イソプレン−スチレンブロック共重合体
１２．５ 部 （商品名
カリフレックス ＴＲ−１１０７） スチレン−イソ
プレン−スチレンブロック共重合体
１２．５ 部 （商品名 カリフレックス Ｔ
Ｒ−１１１１） 流動パラフィン
５１．０ 部 ブチルヒドロキシ
トルエン
２．０ 部 粘着付与剤
（ロジンエステル）
１５．０ 部 （商品名
ＫＥ−３１１）
クロタミトン
５．０ 部 ４−ビフェニル酢酸
２．０ 部 この処方で上記の
製造法に従い作成し、所望の大きさに切断し貼付剤とし
た。Example 4 Styrene-isoprene-styrene block copolymer 12.5 parts (trade name
Califlex TR-1107) Styrene-isoprene-styrene block copolymer
12.5 parts (Product name: Califlex T
R-1111) Liquid paraffin
51.0 parts butylated hydroxytoluene
2.0 parts Tackifier (rosin ester)
15.0 parts (Product name KE-311) Crotamiton
5.0 parts 4-biphenylacetic acid
2.0 parts This formulation was prepared according to the above manufacturing method and cut into desired sizes to prepare a patch.
【００１６】実施例５
スチレン−イソプレン−スチレンブロック共重合体
２５．０ 部 （商品名
カリフレックス ＴＲ−１１１１） 流動パラフィン
５２．０ 部
ブチルヒドロキシトルエン
２．０
部 クロタミトン
１５．０ 部 粘着付与剤（ロジンエステ
ル）
５．０ 部 （商品名 ＫＥ−３１
１）
４−ビフェニル酢酸
１．０ 部 この処方で上記の製造法に従い作成し
、所望の大きさに切断し貼付剤とした。Example 5 Styrene-isoprene-styrene block copolymer 25.0 parts (trade name
Califlex TR-1111) Liquid paraffin
52.0 copies
butylated hydroxytoluene
2.0
Part Crotamiton
15.0 parts Tackifier (rosin ester)
5.0 parts (Product name KE-31
1) 4-biphenylacetic acid
1.0 part This formulation was prepared according to the above manufacturing method and cut into desired sizes to prepare a patch.
【００１７】実施例６
スチレン−イソプレン−スチレンブロック共重合体
２１．０ 部 （商品名
カリフレックス ＴＲ−１１１１） ポリイソブチレ
ン（エクソン化学製）
５．０ 部 流動パラフィン
５３．５ 部 ブ
チルヒドロキシトルエン
２．０ 部
粘着付与剤（ロジンエステル）
１５．０
部 （商品名 ＫＥ−３１１）
クロタミトン
２．５ 部 ４−ビフェニル酢酸
１．０ 部 この処方で上記の
製造法に従い作成し、所望の大きさに切断し貼付剤とし
た。Example 6 Styrene-isoprene-styrene block copolymer 21.0 parts (trade name
Califlex TR-1111) Polyisobutylene (manufactured by Exxon Chemical)
5.0 parts liquid paraffin
53.5 parts butylated hydroxytoluene
2.0 parts Tackifier (rosin ester)
15.0
(Product name KE-311) Crotamiton
2.5 parts 4-biphenylacetic acid
1.0 part This formulation was prepared according to the above manufacturing method and cut into desired sizes to prepare a patch.
【００１８】実施例７
スチレン−イソプレン−スチレンブロック共重合体
２０．０ 部 （商品名
カリフレックス ＴＲ−１１１１） ポリイソブチレ
ン（エクソン化学製）
５．０ 部 流動パラフィン
５２．０ 部 ブ
チルヒドロキシトルエン
２．０ 部
粘着付与剤（ロジンエステル）
１５．０
部 （商品名 ＫＥ−３１１）
クロタミトン
５．０ 部 ４−ビフェニル酢酸
１．０ 部 この処方で上記の
製造法に従い作成し、所望の大きさに切断し貼付剤とし
た。Example 7 Styrene-isoprene-styrene block copolymer 20.0 parts (trade name
Califlex TR-1111) Polyisobutylene (manufactured by Exxon Chemical)
5.0 parts liquid paraffin
52.0 parts butylated hydroxytoluene
2.0 parts Tackifier (rosin ester)
15.0
(Product name KE-311) Crotamiton
5.0 parts 4-biphenylacetic acid
1.0 part This formulation was prepared according to the above manufacturing method and cut into desired sizes to prepare a patch.
【００１９】実施例８
スチレン−イソプレン−スチレンブロック共重合体
１８．０ 部 （商品名
カリフレックス ＴＲ−１１１１） ポリイソブチレ
ン（エクソン化学製）
５．０ 部 流動パラフィン
４９．０ 部 ブ
チルヒドロキシトルエン
２．０ 部
粘着付与剤（ロジンエステル）
１５．０
部 （商品名 ＫＥ−３１１）
クロタミトン
１０．０ 部 ４−ビフェニル酢酸
１．０ 部 この処方で上記の
製造法に従い作成し、所望の大きさに切断し貼付剤とし
た。Example 8 Styrene-isoprene-styrene block copolymer 18.0 parts (trade name
Califlex TR-1111) Polyisobutylene (manufactured by Exxon Chemical)
5.0 parts liquid paraffin
49.0 parts butylated hydroxytoluene
2.0 parts Tackifier (rosin ester)
15.0
(Product name KE-311) Crotamiton
10.0 parts 4-biphenylacetic acid
1.0 part This formulation was prepared according to the above manufacturing method and cut into desired sizes to prepare a patch.
【００２０】実施例９
スチレン−イソプレン−スチレンブロック共重合体
２０．０ 部 （商品名
カリフレックス ＴＲ−１１１１） ポリイソブチレ
ン（エクソン化学製）
５．０ 部 流動パラフィン
５２．０ 部 ブ
チルヒドロキシトルエン
２．０ 部
粘着付与剤（ロジンエステル）
１５．０
部 （商品名 ＫＥ−３１１）
クロタミトン
５．０ 部 ４−ビフェニル酢酸エチル
１．０ 部 この処方で上記の製造法
に従い作成し、所望の大きさに切断し貼付剤とした。Example 9 Styrene-isoprene-styrene block copolymer 20.0 parts (trade name
Califlex TR-1111) Polyisobutylene (manufactured by Exxon Chemical)
5.0 parts liquid paraffin
52.0 parts butylated hydroxytoluene
2.0 parts Tackifier (rosin ester)
15.0
(Product name KE-311) Crotamiton
5.0 parts ethyl 4-biphenylacetate
1.0 part This formulation was prepared according to the above manufacturing method and cut into desired sizes to prepare a patch.
【００２１】実施例１０
スチレン−イソプレン−スチレンブロック共重合体
２０．０ 部 （商品名
カリフレックス ＴＲ−１１１１） ポリイソブチレ
ン（エクソン化学製）
５．０ 部 流動パラフィン
５０．０ 部 ブ
チルヒドロキシトルエン
２．０ 部
粘着付与剤（ロジンエステル）
１５．０
部 （商品名 ＫＥ−３１１）
クロタミトン
６．０ 部 インドメタシン
２．０ 部 この処方で上
記の製造法に従い作成し、所望の大きさに切断し貼付剤
とした。Example 10 Styrene-isoprene-styrene block copolymer 20.0 parts (trade name
Califlex TR-1111) Polyisobutylene (manufactured by Exxon Chemical)
5.0 parts liquid paraffin
50.0 parts butylated hydroxytoluene
2.0 parts Tackifier (rosin ester)
15.0
(Product name KE-311) Crotamiton
6.0 parts indomethacin
2.0 parts This formulation was prepared according to the above manufacturing method and cut into desired sizes to prepare a patch.
【００２２】実施例１１
スチレン−イソプレン−スチレンブロック共重合体
１９．０ 部 （商品名
カリフレックス ＴＲ−１１１１） ポリイソブチレ
ン（エクソン化学製）
５．０ 部 流動パラフィン
４９．０ 部 ブ
チルヒドロキシトルエン
２．０ 部
粘着付与剤（ロジンエステル）
１５．０
部 （商品名 ＫＥ−３１１）
クロタミトン
７．０ 部 ケトプロフェン
３．０ 部 この処方で上
記の製造法に従い作成し、所望の大きさに切断し貼付剤
とした。Example 11 Styrene-isoprene-styrene block copolymer 19.0 parts (trade name
Califlex TR-1111) Polyisobutylene (manufactured by Exxon Chemical)
5.0 parts liquid paraffin
49.0 parts butylated hydroxytoluene
2.0 parts Tackifier (rosin ester)
15.0
(Product name KE-311) Crotamiton
7.0 parts Ketoprofen
3.0 parts This formulation was prepared according to the above manufacturing method and cut into desired sizes to prepare a patch.
【００２８】実施例１２
スチレン−イソプレン−スチレンブロック共重合体
２０．０ 部 （商品名
カリフレックス ＴＲ−１１１１） ポリイソブチレ
ン（エクソン化学製）
５．０ 部 流動パラフィン
５２．０ 部 ブ
チルヒドロキシトルエン
２．０ 部
粘着付与剤（ロジンエステル）
１５．０
部 （商品名 ＫＥ−３１１）
クロタミトン
５．０ 部 フルルビプロフェン
１．０ 部 この処方で上記の
製造法に従い作成し、所望の大きさに切断し貼付剤とし
た。Example 12 Styrene-isoprene-styrene block copolymer 20.0 parts (trade name
Califlex TR-1111) Polyisobutylene (manufactured by Exxon Chemical)
5.0 parts liquid paraffin
52.0 parts butylated hydroxytoluene
2.0 parts Tackifier (rosin ester)
15.0
(Product name KE-311) Crotamiton
5.0 parts flurbiprofen
1.0 part This formulation was prepared according to the above manufacturing method and cut into desired sizes to prepare a patch.
【００２９】実施例１３
スチレン−イソプレン−スチレンブロック共重合体
１９．０ 部 （商品名
カリフレックス ＴＲ−１１１１） ポリイソブチレ
ン（エクソン化学製）
５．０ 部 流動パラフィン
４９．０ 部 ブ
チルヒドロキシトルエン
２．０ 部
粘着付与剤（ロジンエステル）
１５．０
部 （商品名 ＫＥ−３１１）
クロタミトン
７．０ 部 ロキソプロフェンナトリウム
３．０ 部この処方で上記の製造法に従い
作成し、所望の大きさに切断し貼付剤とした。Example 13 Styrene-isoprene-styrene block copolymer 19.0 parts (trade name
Califlex TR-1111) Polyisobutylene (manufactured by Exxon Chemical)
5.0 parts liquid paraffin
49.0 parts butylated hydroxytoluene
2.0 parts Tackifier (rosin ester)
15.0
(Product name KE-311) Crotamiton
7.0 parts loxoprofen sodium
3.0 parts This formulation was prepared according to the above manufacturing method and cut into desired sizes to prepare patches.
【００３０】実施例１４
スチレン−イソプレン−スチレンブロック共重合体
２０．０ 部 （商品名
カリフレックス ＴＲ−１１１１） ポリイソブチレ
ン（エクソン化学製）
５．０ 部 流動パラフィン
５２．０ 部 ブ
チルヒドロキシトルエン
２．０ 部
粘着付与剤（ロジンエステル）
１５．０
部 （商品名 ＫＥ−３１１）
クロタミトン
５．０ 部 ジクロフェナックナトリウム
１．０ 部この処方で上記の製造法に従い
作成し、所望の大きさに切断し貼付剤とした。Example 14 Styrene-isoprene-styrene block copolymer 20.0 parts (trade name
Califlex TR-1111) Polyisobutylene (manufactured by Exxon Chemical)
5.0 parts liquid paraffin
52.0 parts butylated hydroxytoluene
2.0 parts Tackifier (rosin ester)
15.0
(Product name KE-311) Crotamiton
5.0 parts diclofenac sodium
1.0 parts of this formulation was prepared according to the above manufacturing method and cut into desired sizes to prepare patches.
【００３１】実施例１５
スチレン−イソプレン−スチレンブロック共重合体
２０．０ 部 （商品名
カリフレックス ＴＲ−１１１１） ポリイソブチレ
ン（エクソン化学製）
５．０ 部 流動パラフィン
５０．０ 部 ブ
チルヒドロキシトルエン
２．０ 部
粘着付与剤（ロジンエステル）
１５．０
部 （商品名 ＫＥ−３１１）
クロタミトン
６．０ 部 ピロキシカム
２．０ 部この処方で上記
の製造法に従い作成し、所望の大きさに切断し貼付剤と
した。Example 15 Styrene-isoprene-styrene block copolymer 20.0 parts (trade name
Califlex TR-1111) Polyisobutylene (manufactured by Exxon Chemical)
5.0 parts liquid paraffin
50.0 parts butylated hydroxytoluene
2.0 parts Tackifier (rosin ester)
15.0
(Product name KE-311) Crotamiton
6.0 parts piroxicam
2.0 parts of this formulation was prepared according to the above manufacturing method and cut into desired sizes to prepare patches.
【００３２】実施例１６
スチレン−イソプレン−スチレンブロック共重合体
２１．０ 部 （商品名
カリフレックス ＴＲ−１１１１） ポリイソブチレ
ン（エクソン化学製）
５．０ 部 流動パラフィン
５３．５ 部 ブ
チルヒドロキシトルエン
２．０ 部
粘着付与剤（ロジンエステル）
１５．０
部 （商品名 ＫＥ−３１１）
クロタミトン
３．０ 部 メロキシカム
０．５ 部この処方で上記
の製造法に従い作成し、所望の大きさに切断し貼付剤と
した。Example 16 Styrene-isoprene-styrene block copolymer 21.0 parts (trade name
Califlex TR-1111) Polyisobutylene (manufactured by Exxon Chemical)
5.0 parts liquid paraffin
53.5 parts butylated hydroxytoluene
2.0 parts Tackifier (rosin ester)
15.0
(Product name KE-311) Crotamiton
Part 3.0 Meloxicam
0.5 parts of this formulation was prepared according to the above manufacturing method and cut into desired sizes to prepare patches.
【００３３】実施例１７
スチレン−イソプレン−スチレンブロック共重合体
２１．０ 部 （商品名
カリフレックス ＴＲ−１１１１） ポリイソブチレ
ン（エクソン化学製）
５．０ 部 流動パラフィン
５３．５ 部 ブ
チルヒドロキシトルエン
２．０ 部
粘着付与剤（ロジンエステル）
１５．０
部 （商品名 ＫＥ−３１１）
クロタミトン
３．０ 部 ベルモプロフェン
０．５ 部この処方で上記の製
造法に従い作成し、所望の大きさに切断し貼付剤とした
。Example 17 Styrene-isoprene-styrene block copolymer 21.0 parts (trade name
Califlex TR-1111) Polyisobutylene (manufactured by Exxon Chemical)
5.0 parts liquid paraffin
53.5 parts butylated hydroxytoluene
2.0 parts Tackifier (rosin ester)
15.0
(Product name KE-311) Crotamiton
3.0 parts Belmoprofen
0.5 parts of this formulation was prepared according to the above manufacturing method and cut into desired sizes to prepare patches.
【００３４】実施例１８
スチレン−イソプレン−スチレンブロック共重合体
２１．０ 部 （商品名
カリフレックス ＴＲ−１１１１） ポリイソブチレ
ン（エクソン化学製）
５．０ 部 流動パラフィン
５３．５ 部 ブ
チルヒドロキシトルエン
２．０ 部
粘着付与剤（ロジンエステル）
１５．０
部 （商品名 ＫＥ−３１１）
クロタミトン
３．０ 部 ロルノキシカム
０．５ 部この処方で上記の
製造法に従い作成し、所望の大きさに切断し貼付剤とし
た。Example 18 Styrene-isoprene-styrene block copolymer 21.0 parts (trade name
Califlex TR-1111) Polyisobutylene (manufactured by Exxon Chemical)
5.0 parts liquid paraffin
53.5 parts butylated hydroxytoluene
2.0 parts Tackifier (rosin ester)
15.0
(Product name KE-311) Crotamiton
3.0 parts lornoxicam
0.5 parts of this formulation was prepared according to the above manufacturing method and cut into desired sizes to prepare patches.
【００３５】実施例１９
スチレン−イソプレン−スチレンブロック共重合体
２１．０ 部 （商品名
カリフレックス ＴＲ−１１１１） ポリイソブチレ
ン（エクソン化学製）
５．０ 部 流動パラフィン
５３．５ 部 ブ
チルヒドロキシトルエン
２．０ 部
粘着付与剤（ロジンエステル）
１５．０
部 （商品名 ＫＥ−３１１）
クロタミトン
３．０ 部 ケトロラック
０．５ 部この処方で上記
の製造法に従い作成し、所望の大きさに切断し貼付剤と
した。Example 19 Styrene-isoprene-styrene block copolymer 21.0 parts (trade name
Califlex TR-1111) Polyisobutylene (manufactured by Exxon Chemical)
5.0 parts liquid paraffin
53.5 parts butylated hydroxytoluene
2.0 parts Tackifier (rosin ester)
15.0
(Product name KE-311) Crotamiton
3.0 parts Ketorolac
0.5 parts of this formulation was prepared according to the above manufacturing method and cut into desired sizes to prepare patches.
【００３６】実施例２０
スチレン−イソプレン−スチレンブロック共重合体
２３．０ 部 （商品名
カリフレックス ＴＲ−１１１１） ポリイソブチレ
ン（エクソン化学製）
５．０ 部 流動パラフィン
５３．９ 部 ブ
チルヒドロキシトルエン
２．０ 部
粘着付与剤（ロジンエステル）
１５．０
部 （商品名 ＫＥ−３１１）
クロタミトン
１．０ 部 フェンタニール
０．１ 部この処方で上記の
製造法に従い作成し、所望の大きさに切断し貼付剤とし
た。Example 20 Styrene-isoprene-styrene block copolymer 23.0 parts (trade name
Califlex TR-1111) Polyisobutylene (manufactured by Exxon Chemical)
5.0 parts liquid paraffin
53.9 parts Butylated hydroxytoluene
2.0 parts Tackifier (rosin ester)
15.0
(Product name KE-311) Crotamiton
1.0 part fentanyl
0.1 part of this formulation was prepared according to the above manufacturing method and cut into desired sizes to prepare patches.
【００３７】実施例２１
スチレン−イソプレン−スチレンブロック共重合体
２３．０ 部 （商品名
カリフレックス ＴＲ−１１１１） ポリイソブチレ
ン（エクソン化学製）
５．０ 部 流動パラフィン
５３．９ 部 ブ
チルヒドロキシトルエン
２．０ 部
粘着付与剤（ロジンエステル）
１５．０
部 （商品名 ＫＥ−３１１）
クロタミトン
１．０ 部 エプタゾシン
０．１ 部この処方で上記
の製造法に従い作成し、所望の大きさに切断し貼付剤と
した。Example 21 Styrene-isoprene-styrene block copolymer 23.0 parts (trade name
Califlex TR-1111) Polyisobutylene (manufactured by Exxon Chemical)
5.0 parts liquid paraffin
53.9 parts Butylated hydroxytoluene
2.0 parts Tackifier (rosin ester)
15.0
(Product name KE-311) Crotamiton
1.0 part eptazocine
0.1 part of this formulation was prepared according to the above manufacturing method and cut into desired sizes to prepare patches.
【００３８】比較例１
実施例７においてクロタミトンを除き後は同様な方法で
貼付剤を得た。Comparative Example 1 A patch was obtained in the same manner as in Example 7 except that crotamiton was removed.
【００３９】試験例１（薬物放出試験）実施例６、７、
８、比較例１にて得られた貼付剤からの水中への薬物の
放出試験を行い、貼付剤中からの薬物放出率を求めた。
その結果を表１に示す。Test Example 1 (Drug Release Test) Examples 6, 7,
8. A drug release test into water from the patch obtained in Comparative Example 1 was conducted to determine the drug release rate from the patch. The results are shown in Table 1.
【００４０】[0040]
【表１】[Table 1]
【００４１】試験例２（ヘアレスマウス皮膚透過試験）
実施例７及び対照薬として既発売の４−ビフェニル酢酸
含有軟膏（商品名：ナパゲルン軟膏）を用いヘアレスマ
ウス皮膚透過試験を行い、８時間後の４−ビフェニル酢
酸の皮膚透過量及び利用率（皮膚透過率）を求めた。そ
の結果を表２に示す。Test Example 2 (hairless mouse skin permeation test)
A hairless mouse skin permeation test was conducted using Example 7 and a commercially available ointment containing 4-biphenylacetic acid (trade name: Napageln ointment) as a control drug. Transmittance) was determined. The results are shown in Table 2.
【００４２】[0042]
【表２】[Table 2]
【００４３】[0043]
【作用】試験例１の薬物放出試験において、本発明のス
チレン−イソプレン−スチレンブロック共重合体、クロ
タミトン及び消炎鎮痛薬を必須成分とする貼付剤は、ク
ロタミトンを含有しない比較例の貼付剤との比較におい
て約２倍の薬物放出率を示す。又、試験例２のヘアレス
マスウ皮膚透過試験において本発明の貼付剤は比較薬で
ある市販薬（商品名：ナパゲルン軟膏）との比較におい
て皮膚透過量で約２倍、利用率（皮膚透過率）で約４倍
の作用を示した。又、本発明の貼付剤は物理的性質（接
着力、投錨力、凝集力、粘着性等）の面でも大変好まし
い作用を有した。[Effect] In the drug release test of Test Example 1, the patch containing the styrene-isoprene-styrene block copolymer of the present invention, crotamiton, and an anti-inflammatory analgesic as essential ingredients was found to be superior to the comparative patch that did not contain crotamiton. In comparison, the drug release rate is about twice as high. In addition, in the hairless trout skin permeation test of Test Example 2, the patch of the present invention showed approximately twice the amount of skin permeation and the utilization rate (skin permeation rate) of the comparative commercially available drug (trade name: Napagellon Ointment). It showed about 4 times the effect. Furthermore, the adhesive patch of the present invention had very favorable effects in terms of physical properties (adhesive force, anchoring force, cohesive force, adhesiveness, etc.).
【００４４】[0044]
【発明の効果】本発明の貼付剤は薬物放出性、皮膚透過
量及び皮膚透過率に顕著な作用を有するため、高い薬効
発現性が可能である又、薬効成分である消炎鎮痛薬の使
用量が少なくて済み経済的である。又、本発明の製剤は
貼付剤であるのでゲル軟膏剤あるいは注射剤と違って長
時間貼付でも安定的に薬物放出が可能で持続性に優れる
。このように本発明の貼付剤は薬物放出に最も適した製
剤となり、医薬産業上大変有用である。Effects of the Invention: The patch of the present invention has a remarkable effect on drug release, skin permeation amount, and skin permeation rate, so it is possible to exhibit high drug efficacy. It is economical as it requires less. Moreover, since the preparation of the present invention is a patch, it is possible to stably release the drug even when applied for a long time, and has excellent sustainability, unlike gel ointments or injections. As described above, the adhesive patch of the present invention is a formulation most suitable for drug release, and is very useful in the pharmaceutical industry.
Claims (3)
ック共重合体、クロタミトン及び消炎鎮痛薬を必須成分
とする消炎鎮痛貼付剤。1. An anti-inflammatory and analgesic patch containing a styrene-isoprene-styrene block copolymer, crotamiton, and an anti-inflammatory analgesic as essential ingredients.
ック共重合体５〜５０重量％、クロタミトン１〜２０重
量％及び消炎鎮痛薬 ０．１〜１０重量％を必須成分と
する消炎鎮痛貼付剤。2. An anti-inflammatory and analgesic patch containing as essential ingredients 5-50% by weight of a styrene-isoprene-styrene block copolymer, 1-20% by weight of crotamiton, and 0.1-10% by weight of an anti-inflammatory analgesic.
たは４−ビフェニル酢酸エチルエステルであることを特
長とする請求項１または請求項２の消炎鎮痛貼付剤。3. The anti-inflammatory and analgesic patch according to claim 1 or 2, wherein the anti-inflammatory and analgesic agent is 4-biphenylacetic acid or 4-biphenylacetic acid ethyl ester.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11673291A JP3541849B2 (en) | 1991-04-19 | 1991-04-19 | Anti-inflammatory analgesic patch |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11673291A JP3541849B2 (en) | 1991-04-19 | 1991-04-19 | Anti-inflammatory analgesic patch |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003380468A Division JP4157018B2 (en) | 2003-11-10 | 2003-11-10 | Anti-inflammatory analgesic patch |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH04321624A true JPH04321624A (en) | 1992-11-11 |
| JP3541849B2 JP3541849B2 (en) | 2004-07-14 |
Family
ID=14694423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP11673291A Expired - Lifetime JP3541849B2 (en) | 1991-04-19 | 1991-04-19 | Anti-inflammatory analgesic patch |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3541849B2 (en) |
Cited By (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994009777A1 (en) * | 1992-10-30 | 1994-05-11 | Syntex (U.S.A.) Inc. | Transdermal delivery of ketorolac |
| WO1994013283A1 (en) * | 1992-12-17 | 1994-06-23 | Sepracor Inc. | Antipyretic and analgesic methods and compositions containing optically pure r-ketorolac |
| EP0668759A1 (en) * | 1992-11-09 | 1995-08-30 | Pharmetrix Corporation | Transdermal delivery of ketorolac |
| EP0713697A1 (en) | 1994-10-26 | 1996-05-29 | Tokuhon Corporation | Analgesic anti-inflammatory adhesive preparations |
| US5591767A (en) * | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| WO1997042952A1 (en) * | 1996-05-13 | 1997-11-20 | Hisamitsu Pharmaceutical Co., Inc. | Percutaneous tape preparation containing fentanyl |
| WO1998008966A1 (en) | 1996-08-26 | 1998-03-05 | Sankyo Company, Limited | Loxoprofen-containing preparation for external use |
| WO1998024423A1 (en) * | 1996-12-06 | 1998-06-11 | Hisamitsu Pharmaceutical Co., Inc. | Felbinac-containing patch |
| WO1999009988A1 (en) * | 1997-08-27 | 1999-03-04 | Hexal Ag | New pharmaceutical compositions of meloxicam with improved solubility and bioavailability |
| JP2000044476A (en) * | 1998-07-31 | 2000-02-15 | Toko Yakuhin Kogyo Kk | Fentanyl-containing percutaously absorbable administration matrix type patch |
| JP2000178186A (en) * | 1998-10-05 | 2000-06-27 | Yuutoku Yakuhin Kogyo Kk | Percutaneous absorption tape preparation |
| JP2001039864A (en) * | 1999-07-30 | 2001-02-13 | Hisamitsu Pharmaceut Co Inc | Felbinac-containing plaster |
| JP2001097857A (en) * | 1999-10-01 | 2001-04-10 | Teikoku Seiyaku Co Ltd | Felbinac-containing analgesic and antiphlogistic strap for external use |
| US6262121B1 (en) | 1997-07-18 | 2001-07-17 | Teikoku Seiyaku Co., Ltd. | Oily patches for external use containing diclofenac sodium |
| WO2002043711A1 (en) * | 2000-11-29 | 2002-06-06 | Teikoku Seiyaku Co.,Ltd. | Adhesive preparation for external use |
| EP1300143A1 (en) * | 2000-06-01 | 2003-04-09 | Teikoku Seiyaku Co., Ltd. | Patch containing 4-biphenylacetic acid |
| US6620430B2 (en) | 1996-12-06 | 2003-09-16 | Hisamitsu Pharmaceutical Co., Inc. | Plaster containing felbinac |
| JPWO2002098396A1 (en) * | 2001-05-31 | 2004-09-16 | 久光製薬株式会社 | Transdermal patch |
| US6953590B1 (en) | 1998-10-05 | 2005-10-11 | Yutoku Pharmaceutical Ind. Co., Ltd. | Tape material for transcutaneous absorption |
| WO2005102306A1 (en) * | 2004-04-23 | 2005-11-03 | Hisamitsu Pharmaceutical Co., Inc. | Anti-inflammatory analgesic adhesive patch |
| JPWO2004024155A1 (en) * | 2002-09-13 | 2006-01-05 | 久光製薬株式会社 | Patch |
| WO2007069662A1 (en) * | 2005-12-13 | 2007-06-21 | Nitto Denko Corporation | Adhesive preparation |
| JP2008069127A (en) * | 2006-09-15 | 2008-03-27 | Toko Yakuhin Kogyo Kk | Anti-inflammatory and analgesic cream preparation and method for producing the same |
| JP2008100939A (en) * | 2006-10-18 | 2008-05-01 | Nichiban Co Ltd | Percutaneous absorption preparation having little skin irritation |
| JP2011037903A (en) * | 2010-11-26 | 2011-02-24 | Daiichi Sankyo Co Ltd | Antiinflammatory/analgesic composition for external use |
| WO2011074566A1 (en) | 2009-12-15 | 2011-06-23 | 帝國製薬株式会社 | Felbinac-containing transdermal absorption preparation |
| JP2011140501A (en) * | 2011-03-02 | 2011-07-21 | Daiichi Sankyo Co Ltd | Antiinflammatory/analgesic composition for external use |
| US8114434B2 (en) | 2001-05-23 | 2012-02-14 | Tokuhon Corporation | Diclofenac sodium patches for topical treatment of pain |
| WO2012060376A1 (en) * | 2010-11-02 | 2012-05-10 | 帝國製薬株式会社 | Felbinac-containing external patch |
| US8389000B2 (en) | 2006-11-30 | 2013-03-05 | Nipro Patch Co., Ltd. | Adhesive skin patch and method for evaluation of adhesive skin patch |
| US8920820B2 (en) | 2001-12-12 | 2014-12-30 | Boehringer Ingelheim Vetmedica Gmbh | Highly concentrated stable meloxicam solutions for needleless injection |
| US8992980B2 (en) | 2002-10-25 | 2015-03-31 | Boehringer Ingelheim Vetmedica Gmbh | Water-soluble meloxicam granules |
| US9101529B2 (en) | 2009-10-12 | 2015-08-11 | Boehringer Ingelheim Vetmedica Gmbh | Containers for compositions comprising meloxicam |
| US9149480B2 (en) | 2010-03-03 | 2015-10-06 | Boehringer Ingeleheim Vetmedica GmbH | Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats |
| US9795568B2 (en) | 2010-05-05 | 2017-10-24 | Boehringer Ingelheim Vetmedica Gmbh | Low concentration meloxicam tablets |
| US9993557B2 (en) | 2000-06-20 | 2018-06-12 | Boehringer Ingelheim Vetmedica Gmbh | Highly concentrated stable meloxicam solutions |
| US10548901B2 (en) | 2004-02-23 | 2020-02-04 | Boehringer Ingelheim Vetmedica Gmbh | Meloxicam for the treatment of respiratory diseases in pigs |
| KR20220161277A (en) | 2020-03-31 | 2022-12-06 | 니찌방 가부시기가이샤 | patch |
-
1991
- 1991-04-19 JP JP11673291A patent/JP3541849B2/en not_active Expired - Lifetime
Cited By (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994009777A1 (en) * | 1992-10-30 | 1994-05-11 | Syntex (U.S.A.) Inc. | Transdermal delivery of ketorolac |
| EP0668759A1 (en) * | 1992-11-09 | 1995-08-30 | Pharmetrix Corporation | Transdermal delivery of ketorolac |
| EP0668759A4 (en) * | 1992-11-09 | 1996-01-24 | Pharmetrix Corp | Transdermal delivery of ketorolac. |
| WO1994013283A1 (en) * | 1992-12-17 | 1994-06-23 | Sepracor Inc. | Antipyretic and analgesic methods and compositions containing optically pure r-ketorolac |
| US5591767A (en) * | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US5776484A (en) * | 1994-10-26 | 1998-07-07 | Tokuhon Corporation | Analgesic anti-inflammatory adhesive plaster |
| EP0713697A1 (en) | 1994-10-26 | 1996-05-29 | Tokuhon Corporation | Analgesic anti-inflammatory adhesive preparations |
| US5879702A (en) * | 1994-10-26 | 1999-03-09 | Tokuhon Corporation | Analgesic anti-inflammatory adhesive preparations |
| WO1997042952A1 (en) * | 1996-05-13 | 1997-11-20 | Hisamitsu Pharmaceutical Co., Inc. | Percutaneous tape preparation containing fentanyl |
| WO1998008966A1 (en) | 1996-08-26 | 1998-03-05 | Sankyo Company, Limited | Loxoprofen-containing preparation for external use |
| US6248350B1 (en) | 1996-08-26 | 2001-06-19 | Lead Chemical Co., Ltd. | External formulation containing loxoprofen |
| JP2007291118A (en) * | 1996-08-26 | 2007-11-08 | Daiichi Sankyo Co Ltd | Method for producing loxoprofen sodium-containing formulation for external use |
| KR100456668B1 (en) * | 1996-08-26 | 2004-11-10 | 리도 케미칼 가부시키가이샤 | Loxoprofen-containing preparation for external use |
| JP2008074873A (en) * | 1996-08-26 | 2008-04-03 | Daiichi Sankyo Co Ltd | Hydrous external preparation containing sodium loxoprofen |
| AU728797B2 (en) * | 1996-08-26 | 2001-01-18 | Lead Chemical Co., Ltd. | External formulation containing loxoprofen |
| WO1998024423A1 (en) * | 1996-12-06 | 1998-06-11 | Hisamitsu Pharmaceutical Co., Inc. | Felbinac-containing patch |
| US6620430B2 (en) | 1996-12-06 | 2003-09-16 | Hisamitsu Pharmaceutical Co., Inc. | Plaster containing felbinac |
| US6844007B2 (en) | 1996-12-06 | 2005-01-18 | Hisamitsu Pharmaceutical Co., Ltd. | Plaster containing felbinac |
| US6833138B2 (en) | 1996-12-06 | 2004-12-21 | Hisamitsu Pharmaceutical Co., Inc. | Plaster containing felbinac |
| US6262121B1 (en) | 1997-07-18 | 2001-07-17 | Teikoku Seiyaku Co., Ltd. | Oily patches for external use containing diclofenac sodium |
| WO1999009988A1 (en) * | 1997-08-27 | 1999-03-04 | Hexal Ag | New pharmaceutical compositions of meloxicam with improved solubility and bioavailability |
| JP2000044476A (en) * | 1998-07-31 | 2000-02-15 | Toko Yakuhin Kogyo Kk | Fentanyl-containing percutaously absorbable administration matrix type patch |
| JP2000178186A (en) * | 1998-10-05 | 2000-06-27 | Yuutoku Yakuhin Kogyo Kk | Percutaneous absorption tape preparation |
| US6953590B1 (en) | 1998-10-05 | 2005-10-11 | Yutoku Pharmaceutical Ind. Co., Ltd. | Tape material for transcutaneous absorption |
| JP4584381B2 (en) * | 1999-07-30 | 2010-11-17 | 久光製薬株式会社 | Felbinac-containing patch |
| JP2001039864A (en) * | 1999-07-30 | 2001-02-13 | Hisamitsu Pharmaceut Co Inc | Felbinac-containing plaster |
| EP1072261A3 (en) * | 1999-07-30 | 2001-05-16 | Hisamitsu Pharmaceutical Co., Inc. | Felbinac-containing patch |
| JP2001097857A (en) * | 1999-10-01 | 2001-04-10 | Teikoku Seiyaku Co Ltd | Felbinac-containing analgesic and antiphlogistic strap for external use |
| JP4676042B2 (en) * | 1999-10-01 | 2011-04-27 | 帝國製薬株式会社 | Topical analgesic / anti-inflammatory patch containing felbinac |
| WO2002043729A1 (en) * | 1999-10-01 | 2002-06-06 | Teikoku Seiyaku Co., Ltd. | Analgesic and anti-inflammatory patches for external use containing 4-biphenylylylacetic acid |
| US7276641B2 (en) | 1999-10-01 | 2007-10-02 | Teikoku Seiyaku Co., Ltd. | External plaster containing 4-biphenylacetic acid |
| KR100757726B1 (en) * | 1999-10-01 | 2007-09-11 | 데이고꾸세이약꾸가부시끼가이샤 | Analgesic and anti-inflammatory patches for external use containing 4-biphenylyl acetic acid |
| US7094421B2 (en) | 2000-06-01 | 2006-08-22 | Teikoku Seiyaki Co., Ltd. | Plaster containing 4-biphenylacetic acid |
| KR100721748B1 (en) * | 2000-06-01 | 2007-05-25 | 데이고꾸세이약꾸가부시끼가이샤 | Patch containing 4-biphenylacetic acid |
| EP1300143A4 (en) * | 2000-06-01 | 2005-12-07 | Teikoku Seiyaku Kk | Patch containing 4-biphenylacetic acid |
| EP1300143A1 (en) * | 2000-06-01 | 2003-04-09 | Teikoku Seiyaku Co., Ltd. | Patch containing 4-biphenylacetic acid |
| US9993557B2 (en) | 2000-06-20 | 2018-06-12 | Boehringer Ingelheim Vetmedica Gmbh | Highly concentrated stable meloxicam solutions |
| WO2002043711A1 (en) * | 2000-11-29 | 2002-06-06 | Teikoku Seiyaku Co.,Ltd. | Adhesive preparation for external use |
| US6946514B2 (en) | 2000-11-29 | 2005-09-20 | Teikoko Seiyaku Co. Ltd. | Adhesive preparation for external use |
| US8114434B2 (en) | 2001-05-23 | 2012-02-14 | Tokuhon Corporation | Diclofenac sodium patches for topical treatment of pain |
| JPWO2002098396A1 (en) * | 2001-05-31 | 2004-09-16 | 久光製薬株式会社 | Transdermal patch |
| US10098891B2 (en) | 2001-12-12 | 2018-10-16 | Boehringer Ingelheim Vetmedica Gmbh | Highly concentrated stable meloxicam solutions for needleless injection |
| US8920820B2 (en) | 2001-12-12 | 2014-12-30 | Boehringer Ingelheim Vetmedica Gmbh | Highly concentrated stable meloxicam solutions for needleless injection |
| JP4758101B2 (en) * | 2002-09-13 | 2011-08-24 | 久光製薬株式会社 | Patch |
| JPWO2004024155A1 (en) * | 2002-09-13 | 2006-01-05 | 久光製薬株式会社 | Patch |
| US9066955B2 (en) | 2002-10-25 | 2015-06-30 | Boehringer Ingelheim Vetmedica Gmbh | Water-soluble meloxicam granules |
| US8992980B2 (en) | 2002-10-25 | 2015-03-31 | Boehringer Ingelheim Vetmedica Gmbh | Water-soluble meloxicam granules |
| US10548901B2 (en) | 2004-02-23 | 2020-02-04 | Boehringer Ingelheim Vetmedica Gmbh | Meloxicam for the treatment of respiratory diseases in pigs |
| JP4764337B2 (en) * | 2004-04-23 | 2011-08-31 | 久光製薬株式会社 | Anti-inflammatory analgesic patch |
| WO2005102306A1 (en) * | 2004-04-23 | 2005-11-03 | Hisamitsu Pharmaceutical Co., Inc. | Anti-inflammatory analgesic adhesive patch |
| WO2007069662A1 (en) * | 2005-12-13 | 2007-06-21 | Nitto Denko Corporation | Adhesive preparation |
| JP2008069127A (en) * | 2006-09-15 | 2008-03-27 | Toko Yakuhin Kogyo Kk | Anti-inflammatory and analgesic cream preparation and method for producing the same |
| JP2008100939A (en) * | 2006-10-18 | 2008-05-01 | Nichiban Co Ltd | Percutaneous absorption preparation having little skin irritation |
| US8389000B2 (en) | 2006-11-30 | 2013-03-05 | Nipro Patch Co., Ltd. | Adhesive skin patch and method for evaluation of adhesive skin patch |
| US9101529B2 (en) | 2009-10-12 | 2015-08-11 | Boehringer Ingelheim Vetmedica Gmbh | Containers for compositions comprising meloxicam |
| US9186296B2 (en) | 2009-10-12 | 2015-11-17 | Boehringer Ingelheim Vetmedica Gmbh | Containers for compositions comprising meloxicam |
| WO2011074566A1 (en) | 2009-12-15 | 2011-06-23 | 帝國製薬株式会社 | Felbinac-containing transdermal absorption preparation |
| US9149480B2 (en) | 2010-03-03 | 2015-10-06 | Boehringer Ingeleheim Vetmedica GmbH | Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats |
| US9795568B2 (en) | 2010-05-05 | 2017-10-24 | Boehringer Ingelheim Vetmedica Gmbh | Low concentration meloxicam tablets |
| US9943486B2 (en) | 2010-05-05 | 2018-04-17 | Boehringer Ingelheim Vetmedica Gmbh | Low concentration meloxicam tablets |
| WO2012060376A1 (en) * | 2010-11-02 | 2012-05-10 | 帝國製薬株式会社 | Felbinac-containing external patch |
| JP2011037903A (en) * | 2010-11-26 | 2011-02-24 | Daiichi Sankyo Co Ltd | Antiinflammatory/analgesic composition for external use |
| JP2011140501A (en) * | 2011-03-02 | 2011-07-21 | Daiichi Sankyo Co Ltd | Antiinflammatory/analgesic composition for external use |
| KR20220161277A (en) | 2020-03-31 | 2022-12-06 | 니찌방 가부시기가이샤 | patch |
Also Published As
| Publication number | Publication date |
|---|---|
| JP3541849B2 (en) | 2004-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH04321624A (en) | Antiphlogistic analgestic plaster | |
| CA2200068C (en) | A preparation for external use and a patch having the preparation attached thereto | |
| KR100868377B1 (en) | Analgestic anti-inflammatory patch for topical application | |
| JP4627985B2 (en) | Transdermal patch | |
| JP6054013B2 (en) | Patch preparation | |
| JP5351518B2 (en) | External pharmaceutical composition and patch | |
| JP4854163B2 (en) | Patch containing anti-inflammatory agent | |
| US9918945B2 (en) | Ropinirole-containing patch and package thereof | |
| EP1121941B1 (en) | Sorbefacients and preparations for percutaneous absorption containing the same | |
| WO2002032431A1 (en) | Compositions for external preparations | |
| US20140112974A1 (en) | Ropinirole-containing patch and package thereof | |
| JP4614881B2 (en) | Patch containing non-steroidal anti-inflammatory analgesic | |
| JP3499247B2 (en) | Patch containing felbinac | |
| JP4625157B2 (en) | Indomethacin patch | |
| JP2002226366A (en) | Liniment preparation for external use | |
| JP6087839B2 (en) | Tolterodine-containing patch | |
| JP5584379B2 (en) | Transdermal absorption enhancer and patch containing the same | |
| JP2010280634A (en) | Anti-inflammatory analgesic plaster | |
| JP4157018B2 (en) | Anti-inflammatory analgesic patch | |
| JP4584381B2 (en) | Felbinac-containing patch | |
| EP1197212A1 (en) | Adhesive preparation for percutaneous absorption | |
| JPH07316045A (en) | Plaster | |
| JP2005529150A (en) | Matrix-type patch with bronchodilator | |
| CA2284625A1 (en) | Adhesive for percutaneously absorbable patch and percutaneously absorbable patch | |
| WO2019167694A1 (en) | Methylphenidate-containing transdermal patch |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20031111 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040129 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20040323 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term | ||
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120409 Year of fee payment: 8 |